Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» heart disease
heart disease
Novo Nordisk says Wegovy can help heart disease patients—and not just because it produces weight loss
Novo Nordisk says Wegovy can help heart disease patients—and not just because it produces weight loss
Fierce Pharma
Novo Nordisk
Wegovy
heart disease
cardiovascular disease
clinical trials
Flag link:
First look at Verve study data offer base editing ‘proof of principle’
First look at Verve study data offer base editing ‘proof of principle’
BioPharma Dive
Verve Therapeutics
heart disease
gene editing
Flag link:
Verve gets FDA green light to run base editing study in US
Verve gets FDA green light to run base editing study in US
BioPharma Dive
Verve Therapeutics
FDA
gene editing
heart disease
clinical trials
Flag link:
Pfizer Lawsuit Seeks to Block Generic Copy of Heart Disease Blockbuster
Pfizer Lawsuit Seeks to Block Generic Copy of Heart Disease Blockbuster
BioSpace
Pfizer
generics
legal
Vyndamax
heart disease
patents
tafamidis
Dexcel Pharma
Flag link:
Evox Therapeutics to advance gene therapy for treatment of heart disease
Evox Therapeutics to advance gene therapy for treatment of heart disease
Biopharma Reporter
Evox Therapeutics
gene therapy
Mount Sinai
heart disease
cardiomyocytes
Flag link:
Agepha Pharma gets ancient gout remedy colchicine across FDA finish line for heart disease
Agepha Pharma gets ancient gout remedy colchicine across FDA finish line for heart disease
Fierce Pharma
Agepha Pharma
FDA
colchicine
heart disease
Lodoco
Flag link:
Verve partners with Lilly on gene editing therapy for heart disease
Verve partners with Lilly on gene editing therapy for heart disease
BioPharma Dive
Eli Lilly
Verve Therapeutics
heart disease
gene editing
Flag link:
XyloCor wraps up PhII for heart disease gene therapy, plans for pivotal trial
XyloCor wraps up PhII for heart disease gene therapy, plans for pivotal trial
Endpoints
XyloCor Therapeutics
gene therapy
heart disease
clinical trials
Flag link:
Study: Base Editing Shows Promise In Treating Heart Disease
Study: Base Editing Shows Promise In Treating Heart Disease
BioSpace
gene editing
base editing
heart disease
heart damage
Flag link:
Could Amgen's Heart Disease Candidate Generate Billions in Sales?
Could Amgen's Heart Disease Candidate Generate Billions in Sales?
Motley Fool
Amgen
heart disease
olpasiran
Flag link:
Arrowhead Gets $250M in Royalty Deal for Cardio Drug Heading to Phase 3
Arrowhead Gets $250M in Royalty Deal for Cardio Drug Heading to Phase 3
MedCity News
Amgen
Arrowhead Pharmaceuticals
olpasiran
heart disease
Flag link:
Amgen to test new way to lower heart risk with large drug trial
Amgen to test new way to lower heart risk with large drug trial
BioPharma Dive
Amgen
clinical trials
heart disease
olpasiran
Flag link:
Rocket inks Renovacor buyout to propel its heart disease gene therapy ambitions
Rocket inks Renovacor buyout to propel its heart disease gene therapy ambitions
Fierce Biotech
Rocket Pharmaceuticals
M&A
gene therapy
Renovacor
heart disease
Flag link:
AstraZeneca axes Moderna-partnered, phase 2 heart disease drug plus a Wee inhibitor
AstraZeneca axes Moderna-partnered, phase 2 heart disease drug plus a Wee inhibitor
Fierce Biotech
AstraZeneca
Moderna Therapeutics
heart disease
MRNA
Wee1 inhibitors
Flag link:
Novartis finalizes deal to make new heart drug widely available in England
Novartis finalizes deal to make new heart drug widely available in England
BioPharma Dive
UK
Novartis
Leqvio
heart disease
cholesterol
Flag link:
Bayer's Farxiga rival Kerendia scores long-awaited kidney and heart disease nod for Type 2 diabetes patients
Bayer's Farxiga rival Kerendia scores long-awaited kidney and heart disease nod for Type 2 diabetes patients
Fierce Pharma
Bayer
finerenone
Kerendia
kidney disease
heart disease
diabetes
type 2 diabetes
Farxiga
Flag link:
Gene editing biotech Verve indicates a swift swerve onto Wall Street, asking for $100M IPO
Gene editing biotech Verve indicates a swift swerve onto Wall Street, asking for $100M IPO
Fierce Biotech
Verve Therapeutics
IPOs
gene editing
heart disease
Flag link:
How a New AI Algorithm Could Help in the Early Detection of Heart Disease
How a New AI Algorithm Could Help in the Early Detection of Heart Disease
Xtalks
artificial intelligence
Mayo Clinic
Anumana
low ejection fraction
diagnostics
heart disease
Flag link:
Combining AstraZeneca's 'good' cholesterol booster with PCSK9 inhibition shows promise in heart disease
Combining AstraZeneca's 'good' cholesterol booster with PCSK9 inhibition shows promise in heart disease
Fierce Biotech
AstraZeneca
heart disease
MEDI5884
Flag link:
XyloCor bags $23M to expand heart disease gene therapy R&D
XyloCor bags $23M to expand heart disease gene therapy R&D
Fierce Biotech
XyloCor Therapeutics
gene therapy
VEGF
heart disease
clinical trials
R&D
Flag link:
Pages
1
2
3
4
next ›
last »